CareCloud expands common stock availability

Published 08/02/2025, 00:02
CareCloud expands common stock availability

CareCloud, Inc. (NASDAQ:CCLD), a provider of healthcare IT solutions with a market capitalization of $67.5 million and impressive year-to-date gains of 11.5%, announced on Monday an amendment to its certificate of incorporation, effectively increasing the number of authorized shares of common stock from 35 million to 85 million. This change was approved by shareholders at a special meeting held on January 27, 2025, and the amendment was filed with the Secretary of State of Delaware on February 5, 2025.

The expansion of common stock availability is a strategic move that could potentially facilitate future corporate activities, including but not limited to, fundraising efforts, stock-based compensation, and other business development initiatives. According to InvestingPro data, the company maintains a GREAT financial health score and analysts have set price targets ranging from $3.50 to $7.00, suggesting potential upside. The company’s filing indicated that the amendment was detailed in a proxy statement filed on December 5, 2024, and became effective immediately upon filing with the state of Delaware.

CareCloud, previously known as MTBC, Inc. and Medical (TASE:PMCN) Transcription Billing, Corp, is headquartered in Somerset, New Jersey, and operates under the SIC code for prepackaged software services. The company’s common stock, along with its 8.75% Series A and Series B Cumulative Redeemable Perpetual Preferred Stock, is listed on the Nasdaq Global Market under the symbols CCLD, CCLDP, and CCLDO, respectively.

The SEC filing also included a safe harbor statement, cautioning that any forward-looking statements are not guarantees of future performance and actual results may differ materially. The company emphasized that it does not have an obligation to update any forward-looking statements post-publication. For investors seeking deeper insights, InvestingPro offers 12 additional investment tips for CCLD and a comprehensive Pro Research Report, providing detailed analysis of the company’s fundamentals and growth prospects.

Investors and stakeholders can refer to the company’s SEC Form 8-K for the complete details of the amendment. This filing serves as the source for the information reported in this article.

In other recent news, healthcare technology solutions provider CareCloud has been downgraded from Buy to Neutral by Roth/MKM due to a weak growth outlook for 2025, despite recent cost-cutting measures. This reassessment follows CareCloud’s third-quarter earnings report, which revealed a slight dip in revenue to $28.5 million but a substantial increase in adjusted EBITDA to $6.8 million. The company also reported a significant improvement in free cash flow, reaching $10.3 million.

On a strategic front, CareCloud has been focusing on leveraging artificial intelligence through its CareCloud CirrusAI platform and launching an in-house remote patient monitoring solution. These are recent developments that aim to drive growth and operational efficiency for the company.

Roth/MKM’s downgrade reflects lowered revenue forecasts for 2025, despite an increase in CareCloud’s cash generation due to cost-cutting measures. However, the company’s financial performance has positioned it to consider resuming payment of its preferred dividends in March 2025. The company’s future growth is anticipated to be driven by strategic partnerships and advancements in AI and remote patient monitoring.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.